Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

NCT03810313 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

493

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated by sponsor due to increased incidences of adverse events of special interest (intraocular inflammation including retinal vasculitis, and retinal vascular occlusion), in patients dosed every 4 weeks beyond 3 initial doses.

Conditions

Central Retinal Vein Occlusion

Interventions

DRUG: Brolucizumab 6 mg
DRUG: Aflibercept 2 mg
OTHER: Sham injection

Sponsor

Novartis Pharmaceuticals